Peptide Companion
Back to catalog
Peptide Companion
single
Sexual Health
Vial: 0.15 mg

HMG (0.15 mg / 75 IU Vial)

Human Menopausal Gonadotropin (HMG) is a purified gonadotropin preparation containing equal amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. In males, HMG is used alongside hCG to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism or infertility. This educational protocol presents a thrice-weekly subcutaneous approach for male fertility support.

Detailed protocol below.

Dosing Schedule
Week/PhaseDose per InjectionVolume per Injection
Weeks 1–1275 IU (0.15 mg)3.0 mL (300 units)
Weeks 13–16 (optional extension)75 IU (0.15 mg)3.0 mL (300 units)
Supplies Needed
  • •Peptide Vials (HMG, 75 IU / 0.15 mg each):
  • •Syringes (3 mL):
  • •Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for each injection site.
References

  • Metrovan Urology – hMG (Menotropin) Overview

    hMG composition: 1:1 blend of FSH and LH derived from postmenopausal urine; standard preparations provide 75 IU FSH + 75 IU LH per vial

    View source

  • Menopur® (Menotropins) Product Monograph

    Human menopausal gonadotropin for subcutaneous administration; each vial contains 75 IU FSH + 75 IU LH activity

    View source

  • ASRM Practice Committee 2020 – Gonadotropin Use for Ovulation Induction

    Clinical guidance on gonadotropin therapy; low-dose protocols (37.5–75 IU) with careful monitoring

    View source

  • ASRM Patient Fact Sheet – Medications for Inducing Ovulation

    Typical gonadotropin protocols: 75–150 IU injected daily for approximately 7–12 days; course may extend if ovaries respond slowly

    View source

  • Metrovan Urology – Hormones and Male Infertility Treatment

    In hypogonadal men, hMG added at 75–150 IU three times weekly if hCG alone insufficient for spermatogenesis

    View source

  • Metrovan Urology – Combined hCG and hMG Therapy

    hCG given 2–3 times weekly stimulates testosterone; hMG provides FSH activity to stimulate sperm production when FSH deficient

    View source

  • Menopur® Monograph – Administration and Reconstitution

    Subcutaneous administration for follicular stimulation; each 75 IU vial typically reconstituted in 1 mL diluent for 75 IU/mL concentration

    View source

  • Menopur® Monograph – Stability and Storage

    Lyophilized menotropin stable at room temperature (15–25 °C) away from light; reconstituted solution should be used immediately to ensure potency and sterility

    View source

  • MedlinePlus – Subcutaneous Injection Instructions

    Use short, thin needle for SC injections; insert at 90° angle into pinched fatty tissue (45° if limited subcutaneous fat); do not reuse needles

    View source

  • MedlinePlus – Injection Site Rotation

    Maintain skin health by alternating injection sites at least one inch apart; avoid areas with irritation, scars, or bruises

    View source

  • Reproductive Medicine and Biology (2018) – Gonadotropin Therapy for Male Infertility

    Review of hCG and hMG combination therapy for hypogonadotropic hypogonadism; FSH supplementation critical for spermatogenesis when hCG monotherapy inadequate

    View source

Educational content adapted from peptidedosages.com. Not medical advice.